200 related articles for article (PubMed ID: 16186804)
21. Histone deacetylase inhibitor FK228 is a potent inducer of human fetal hemoglobin.
Cao H; Stamatoyannopoulos G
Am J Hematol; 2006 Dec; 81(12):981-3. PubMed ID: 16888791
[TBL] [Abstract][Full Text] [Related]
22. Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells.
Kodani M; Igishi T; Matsumoto S; Chikumi H; Shigeoka Y; Nakanishi H; Morita M; Yasuda K; Hitsuda Y; Shimizu E
Oncol Rep; 2005 Mar; 13(3):477-83. PubMed ID: 15706421
[TBL] [Abstract][Full Text] [Related]
23. Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.
Yu XD; Wang SY; Chen GA; Hou CM; Zhao M; Hong JA; Nguyen DM; Schrump DS
Cancer J; 2007; 13(2):105-13. PubMed ID: 17476138
[TBL] [Abstract][Full Text] [Related]
24. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
Vinodhkumar R; Song YS; Devaki T
Biomed Pharmacother; 2008 Feb; 62(2):85-93. PubMed ID: 17644301
[TBL] [Abstract][Full Text] [Related]
25. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.
Skov S; Pedersen MT; Andresen L; Straten PT; Woetmann A; Odum N
Cancer Res; 2005 Dec; 65(23):11136-45. PubMed ID: 16322264
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
27. Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.
Park H; Im JY; Kim J; Choi WS; Kim HS
Int J Mol Med; 2008 Mar; 21(3):325-33. PubMed ID: 18288380
[TBL] [Abstract][Full Text] [Related]
28. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
Xiao JJ; Huang Y; Dai Z; Sadée W; Chen J; Liu S; Marcucci G; Byrd J; Covey JM; Wright J; Grever M; Chan KK
J Pharmacol Exp Ther; 2005 Jul; 314(1):467-75. PubMed ID: 15833893
[TBL] [Abstract][Full Text] [Related]
29. Sustained activation of M-Ras induced by nerve growth factor is essential for neuronal differentiation of PC12 cells.
Sun P; Watanabe H; Takano K; Yokoyama T; Fujisawa J; Endo T
Genes Cells; 2006 Sep; 11(9):1097-113. PubMed ID: 16923128
[TBL] [Abstract][Full Text] [Related]
30. Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells.
Chen G; Li A; Zhao M; Gao Y; Zhou T; Xu Y; Du Z; Zhang X; Yu X
J Proteome Res; 2008 Jul; 7(7):2733-42. PubMed ID: 18549279
[TBL] [Abstract][Full Text] [Related]
31. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: The role of signal transducers and activators of transcription 1 and p21.
Klampfer L; Huang J; Shirasawa S; Sasazuki T; Augenlicht L
Cancer Res; 2007 Sep; 67(18):8477-85. PubMed ID: 17875686
[TBL] [Abstract][Full Text] [Related]
33. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
34. The histone deacetylase inhibitor FK228 may have therapeutic usefulness to prevent suicidal behaviour via upregulation of the guanosine triphosphatase Rap-1.
Emanuele E
Med Hypotheses; 2007; 68(2):451-2. PubMed ID: 16891061
[No Abstract] [Full Text] [Related]
35. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
36. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro.
Lissitzky JC; Parriaux D; Ristorcelli E; Vérine A; Lombardo D; Verrando P
Cancer Res; 2009 Feb; 69(3):802-9. PubMed ID: 19176384
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic H-Ras, FK228, and exogenous H2O2 cooperatively activated the ERK pathway in selective induction of human urinary bladder cancer J82 cell death.
Choudhary S; Wang KK; Wang HC
Mol Carcinog; 2011 Mar; 50(3):215-9. PubMed ID: 21344509
[TBL] [Abstract][Full Text] [Related]
38. Expression of cyclin D3 through Sp1 sites by histone deacetylase inhibitors is mediated with protein kinase C-delta (PKC-delta) signal pathway.
Kim YH; Lim JH; Lee TJ; Park JW; Kwon TK
J Cell Biochem; 2007 Jul; 101(4):987-95. PubMed ID: 17407153
[TBL] [Abstract][Full Text] [Related]
39. Mechanical stress-mediated Runx2 activation is dependent on Ras/ERK1/2 MAPK signaling in osteoblasts.
Kanno T; Takahashi T; Tsujisawa T; Ariyoshi W; Nishihara T
J Cell Biochem; 2007 Aug; 101(5):1266-77. PubMed ID: 17265428
[TBL] [Abstract][Full Text] [Related]
40. Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in p53+/- and p53+/+ mice.
Wei M; Wanibuchi H; Morimura K; Salim EI; Moku M; Doi K; Mitsuhashi M; Masuda C; Shen J; Kinoshita A; Fukushima S
Anticancer Res; 2004; 24(2B):785-90. PubMed ID: 15161027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
